Related Experiment Videos
Cardiovascular complications of ECT in depressed patients with cardiac disease
R J Zielinski1, S P Roose, D P Devanand
1Department of Biological Psychiatry, New York State Psychiatric Institute, NY 10032.
Insights
Electroconvulsive therapy (ECT) is relatively safe for depressed patients with severe cardiovascular disease, though cardiac complications can occur. Close monitoring during ECT is recommended for these patients.
Area of Science:
- Cardiology
- Psychiatry
- Clinical Medicine
Background:
- Major depressive disorder (MDD) poses significant challenges, particularly in patients with pre-existing cardiac conditions.
- Assessing the safety of treatments like electroconvulsive therapy (ECT) in this vulnerable population is crucial.
Purpose of the Study:
- To evaluate the safety and complication rates of ECT in depressed patients with serious cardiovascular disease.
- To compare cardiovascular complication rates between ECT patients with and without cardiac disease.
Main Methods:
- A cohort of 40 patients with MDD and cardiac impairment received ECT and was compared to 40 matched controls without cardiac disease undergoing ECT.
- A subgroup of 21 cardiac patients who previously underwent tricyclic antidepressant trials were analyzed for comparative cardiovascular side effects.
Main Results:
- Patients with cardiac disease experienced a higher incidence of cardiac complications during ECT compared to the control group.
- Most ECT-related cardiac complications were transient and did not impede treatment completion.
- A significant number of cardiac patients discontinued tricyclic antidepressants due to cardiovascular side effects, whereas most completed ECT.
Conclusions:
- ECT can be administered with relative safety to patients suffering from severe cardiovascular disease.
- Close monitoring for arrhythmias and ischemic episodes is essential during ECT for cardiac patients.
Objective:
This study was conducted to determine the safety of electroconvulsive therapy (ECT) for depressed patients with serious cardiac disease.
Method:
The rate of complications in 40 patients with major depressive disorder and left ventricular impairment, ventricular arrhythmias, and/or conduction delay who received ECT was compared to the rate of complications in a matched comparison group of 40 depressed patients without cardiac disease who also received ECT. In addition, 21 of the patients with cardiac illness had received one or more inpatient trials of tricyclic antidepressants before receiving ECT, thereby permitting a comparison of cardiovascular complications of medication and ECT in the same patients.
Results:
The patients with cardiac disease had a significantly higher rate of cardiac complications during ECT than did the comparison group without cardiac disease. The type of preexisting cardiac abnormality strongly predicted the type of cardiac complication that occurred during ECT. However, most of the complications were transitory and did not prevent the completion of ECT. Of the 21 patients with cardiac disease who had received tricyclic trials before ECT, 11 had been forced to discontinue drug treatment because of substantial cardiovascular side effects. In comparison, 38 of the 40 cardiac patients completed the course of ECT.
Conclusions:
With close monitoring for the development of arrhythmia and ischemic episodes, ECT can be given with relative safety to patients with severe cardiovascular disease.